Drug firm Granules India on Thursday said it has received approval from the US health regulator to market Bupropion Hydrochloride extended-release tablets, an antidepressant medication, in the American market.
Granules Pharmaceuticals, Inc (GPI), a wholly-owned subsidiary of the company, has received approval from the US Food & Drug Administration (USFDA) to market the product in strengths of 150 mg and 300 mg, the Hyderabad-based drug firm said in a statement.
The company's product is a generic version of Bausch Health US, LLC's Wellbutrin XL extended-release tablets.
Bupropion Hydrochloride is used as an antidepressant medication to treat major depressive disorder and seasonal affective disorder.
"We are pleased to receive approval of Bupropion Hydrochloride (XL) tablet product within first review cycle of 10 months from filing date. This product will be a valuable addition to our growing modified release product portfolio in the US market," GPI Executive Director Priyanka Chigurupati stated.
This product will be a valuable addition to the company's growing modified release product portfolio in the US market, she added.
According to MAT Dec 2021, IQVIA/IMS Health, the current annual US market for Bupropion Hydrochloride extended-release tablets is around USD 661 million.
Granules noted that it now has a total of 50 abbreviated new drug application (ANDA) approvals from the USFDA.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU